These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. Singleton TP; Strickler JG Pathol Annu; 1992; 27 Pt 1():165-90. PubMed ID: 1346551 [TBL] [Abstract][Full Text] [Related]
24. c-erbB-2 oncogene as a prognostic marker in breast cancer. Perren TJ Br J Cancer; 1991 Mar; 63(3):328-32. PubMed ID: 1672251 [No Abstract] [Full Text] [Related]
25. [Clinical evaluation of ErbB-2 protein in tissue extract using an enzyme immuno assay (ErbB-2 EIA "Nichirei")]. Sugano K; Kitajima M; Ishii M; Koyama H; Kasumi F; Demura R; Mori S; Ohkura H Gan To Kagaku Ryoho; 1994 Sep; 21(12):1957-66. PubMed ID: 7916182 [TBL] [Abstract][Full Text] [Related]
26. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762 [TBL] [Abstract][Full Text] [Related]
27. Relationship between erb-B2 mRNA Expression in Blood and Tissue of Invasive Ductal Carcinoma Breast Cancer Patients and Clinicopathological Characteristics of the Tumors. Moazzezy N; Ebrahimi F; Sisakht MM; Yahyazadeh H; Bouzari S; Oloomi M Asian Pac J Cancer Prev; 2016; 17(1):249-54. PubMed ID: 26838218 [TBL] [Abstract][Full Text] [Related]
28. [Abnormalities and clinical characteristics of growth factors and receptor systems in breast cancer]. Kikuchi K; Ueda M; Ikeda T; Enomoto K; Kitajima M Gan To Kagaku Ryoho; 1994 Jun; 21 Suppl 2():168-71. PubMed ID: 7913599 [TBL] [Abstract][Full Text] [Related]
29. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer. Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827 [TBL] [Abstract][Full Text] [Related]
30. Prognostic factors for recurrent breast cancer: univariate and multivariate analyses including histologic grade and amplification of the c-erbB-2 proto-oncogene. Tsuda H; Tsugane S; Fukutomi T; Nanasawa T; Yamamoto H; Hirohashi S Jpn J Clin Oncol; 1992 Aug; 22(4):244-9. PubMed ID: 1359174 [TBL] [Abstract][Full Text] [Related]
31. Amplification of HER-2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients. Imyanitov EN; Chernitsa OI; Serova OM; Nikoforova IF; Pluzhnikova GF; Knyazev PG Neoplasma; 1993; 40(1):35-9. PubMed ID: 7688867 [TBL] [Abstract][Full Text] [Related]
32. [The expression of c-myb is strongly associated with the presence of estrogen and progesterone receptors in breast cancer]. Guerin M; Barrois M; Riou G C R Acad Sci III; 1988; 307(20):855-61. PubMed ID: 2907731 [TBL] [Abstract][Full Text] [Related]
33. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Tokunaga E; Oki E; Kimura Y; Yamanaka T; Egashira A; Nishida K; Koga T; Morita M; Kakeji Y; Maehara Y Breast Cancer Res Treat; 2007 Mar; 101(3):249-57. PubMed ID: 17006756 [TBL] [Abstract][Full Text] [Related]
34. p185 overexpression in 220 samples of breast cancer undergoing primary surgery: comparison with c-erbB-2 gene amplification. Dalifard I; Daver A; Goussard J; Lorimier G; Gosse-Brun S; Lortholary A; Larra F Int J Mol Med; 1998 May; 1(5):855-61. PubMed ID: 9852307 [TBL] [Abstract][Full Text] [Related]
35. [Study of mdm2 gene amplification in primary breast tumors]. Fontana X; Ferrari P; Abbes M; Monticelli J; Namer M; Bussière F Bull Cancer; 1994 Jul; 81(7):587-92. PubMed ID: 7742600 [TBL] [Abstract][Full Text] [Related]
36. Studies of the HER-2/neu proto-oncogene in human breast cancer. Slamon DJ Cancer Invest; 1990; 8(2):253. PubMed ID: 1976032 [No Abstract] [Full Text] [Related]
37. Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. van de Vijver M; van de Bersselaar R; Devilee P; Cornelisse C; Peterse J; Nusse R Mol Cell Biol; 1987 May; 7(5):2019-23. PubMed ID: 3299059 [TBL] [Abstract][Full Text] [Related]
38. Aberrant methylation of imprinted genes is associated with negative hormone receptor status in invasive breast cancer. Barrow TM; Barault L; Ellsworth RE; Harris HR; Binder AM; Valente AL; Shriver CD; Michels KB Int J Cancer; 2015 Aug; 137(3):537-47. PubMed ID: 25560175 [TBL] [Abstract][Full Text] [Related]
39. Androgen receptor decreases CMYC and KRAS expression by upregulating let-7a expression in ER-, PR-, AR+ breast cancer. Lyu S; Yu Q; Ying G; Wang S; Wang Y; Zhang J; Niu Y Int J Oncol; 2014 Jan; 44(1):229-37. PubMed ID: 24172884 [TBL] [Abstract][Full Text] [Related]
40. [Clinicopathological implications of gene alterations in breast cancer]. Tsuda H Rinsho Byori; 1993 Oct; 41(10):1092-8. PubMed ID: 7902882 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]